Eli Lilly Co v. Amneal Pharma LLC

I. Executive Summary and Procedural Information

• Parties & Counsel:
  • Plaintiff: Eli Lilly and Company (Indiana)
  • Defendant: Amneal Pharmaceuticals LLC (Delaware); Amneal Pharmaceuticals, Inc. (Delaware); Adalvo Limited (Republic of Malta)
  • Plaintiff's Counsel: Morris, Nichols, Arsht & Tunnell LLP
• Case Identification: Eli Lilly and Company v. Amneal Pharmaceuticals LLC, et al., 1:26-cv-00973, D. Del., 08/13/2026
• Venue Allegations: Venue is alleged to be proper as to Amneal Pharmaceuticals LLC and Amneal Pharmaceuticals, Inc. because they are Delaware entities and reside in the district. Venue is alleged to be proper as to Adalvo Limited because it is a foreign corporation that may be sued in any judicial district.
• Core Dispute: Plaintiff alleges that Defendants' proposed generic versions of tirzepatide, filed via Abbreviated New Drug Applications (ANDAs), infringe ten patents covering Plaintiff's Mounjaro® and Zepbound® products.
• Technical Context: The technology relates to tirzepatide, a dual GIP/GLP-1 receptor co-agonist peptide, and its formulations and methods of use for treating type 2 diabetes and obesity, a significant area of the pharmaceutical market.
• Key Procedural History: The action arises from Defendants' submission of ANDA Nos. 221733 and 221732 to the U.S. Food and Drug Administration (FDA), which included Paragraph IV Certifications asserting that the patents-in-suit are invalid, unenforceable, and/or will not be infringed. Adalvo Limited originally filed the ANDAs and subsequently transferred ownership rights to Amneal Pharmaceuticals LLC.

Case Timeline

Date	Event
2014-01-10	'780 Patent Priority Date
2016-10-25	'780 Patent Issue Date
2018-06-22	'820, '623, '755, '756, and '404 Patents Priority Date
2018-07-23	'987, '382, '758, and '740 Patents Priority Date
2022-05-13	FDA Approval of Mounjaro® (tirzepatide)
2022-06-14	'820 Patent Issue Date
2023-11-08	FDA Approval of Zepbound® (tirzepatide)
2024-03-05	'623 Patent Issue Date
2025-05-13	'987 Patent Issue Date
2025-07-01	'382 Patent Issue Date
2025-10-28	'755, '756, and '758 Patents Issue Date
2026-05-05	'740 Patent Issue Date
2026-05-13	Adalvo Limited Original ANDA Filing Date
2026-05-19	'404 Patent Issue Date
2026-07-09	Transfer of ANDA ownership rights to Amneal
2026-07-10	Date of Defendants' Notice Letters
2026-07-13	Lilly's receipt of Defendants' Notice Letters
2026-08-06	Adalvo Limited announces partnership with Gedeon Richter Plc
2026-08-13	First Amended Complaint Filing Date

II. Technology and Patent(s)-in-Suit Analysis

U.S. Patent No. 9,474,780 - "GIP and GLP-1 Co-agonist Compounds"

The Invention Explained

• Problem Addressed: The complaint asserts that this patent is directed at treating type 2 diabetes mellitus (T2DM), a widespread chronic disorder characterized by high blood glucose levels Compl. ¶22 The provided patent document itself does not contain a background section detailing a specific problem.
• The Patented Solution: The patent claims a specific peptide compound, tirzepatide, which acts as a dual agonist for both the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors Compl. ¶24 Compl. ¶58 The invention is a specific chemical structure with modifications, including a fatty acid moiety, designed to achieve this dual activity and provide therapeutic benefit Compl. ¶58 '780 Patent, col. 29:20-30
• Technical Importance: This dual-agonist approach represented a novel mechanism for glycemic control, moving beyond therapies that target only a single incretin pathway Compl. ¶24

Key Claims at a Glance

• The complaint asserts infringement of at least independent claim 1 Compl. ¶59
• Essential elements of Claim 1 include:
  • A compound of a specific 39-amino acid formula (SEQ ID NO: 11).
  • Wherein specific amino acids at positions X1 and X2 are aminoisobutyric acid (Aib).
  • Wherein the lysine (K) at position 20 is chemically modified by conjugation with a specified fatty acid-containing moiety.
  • Wherein the amino acid at position X3 is Phenylalanine (Phe) or 1-Naphthalenalanine (1-Nal).
  • The C-terminal amino acid is optionally amidated.
  • Or a pharmaceutically acceptable salt thereof.

U.S. Patent No. 11,357,820 - "GIP/GLP1 Agonist Compositions"

The Invention Explained

• Problem Addressed: The patent background describes a need for pharmaceutical compositions of tirzepatide that provide acceptable shelf-life stability and in-use stability while also ensuring an acceptable patient injection site experience, noting that issues like pain upon injection can be a concern with subcutaneous formulations '820 Patent, col. 1:23-28 '820 Patent, col. 3:5-24
• The Patented Solution: The patent claims to solve this problem by providing a specific pharmaceutical formulation comprising tirzepatide, sodium chloride (NaCl) as a tonicity agent, and dibasic sodium phosphate as a buffering agent '820 Patent, abstract '820 Patent, col. 1:29-33 This combination is described as providing the desired stability and patient experience '820 Patent, col. 3:45-54
• Technical Importance: Creating a stable, injectable formulation of a complex peptide like tirzepatide that is well-tolerated by patients is critical for its commercial viability and long-term use in treating chronic conditions like diabetes and obesity '820 Patent, col. 1:23-28

Key Claims at a Glance

• The complaint asserts infringement of at least independent claim 1 Compl. ¶76
• Essential elements of Claim 1 include:
  • A pharmaceutical composition comprising tirzepatide, or a pharmaceutically acceptable salt thereof.
  • NaCl at a concentration from 6.2 mg/mL to 9.5 mg/mL.
  • And dibasic sodium phosphate.

U.S. Patent No. 11,918,623 - "GIP/GLP1 Agonist Compositions"

• Technology Synopsis: This patent is directed to a method of treating obesity in a human by administering an effective dose of a pharmaceutical composition containing tirzepatide Compl. ¶92 The patent claims specific concentration ranges for tirzepatide and excipients including dibasic sodium phosphate and NaCl '623 Patent, col. 9:40-54
• Asserted Claims: At least independent claim 1 Compl. ¶93
• Accused Features: The proposed labeling for Defendants' "Proposed ANDA No. 221732 Product" is alleged to instruct and encourage the infringing method of treating obesity Compl. ¶93

U.S. Patent No. 12,295,987 - "Methods of Using a GIP/GLP1 Co-agonist for Diabetes"

• Technology Synopsis: This patent covers a method of treating type 2 diabetes by administering a GIP:GLP-1 Peptide with a specific receptor agonist potency ratio in a multi-dose titration schedule Compl. ¶111 The claim specifies a four-dose escalation regimen where each subsequent dose is a higher percentage of the final dose '987 Patent, col. 24:48-52
• Asserted Claims: At least independent claim 1 Compl. ¶112
• Accused Features: The proposed labeling for Defendants' "Proposed ANDA No. 221733 Product" is alleged to instruct and encourage the claimed multi-step dosing method for treating type 2 diabetes Compl. ¶112

U.S. Patent No. 12,343,382 - "Methods of Using a GIP/GLP1 Co-agonist for Therapy"

• Technology Synopsis: This patent is directed to methods of treating type 2 diabetes and improving weight management by administering an "escalation dose" for at least two weeks followed by a "maintenance dose" Compl. ¶130 Compl. ¶132 The claims specify particular dosages for the escalation and maintenance doses '382 Patent, col. 63:1-13
• Asserted Claims: At least independent claims 1 and 11 Compl. ¶134
• Accused Features: The proposed labeling for Defendants' "Proposed ANDA No. 221733 Product" and "Proposed ANDA No. 221732 Product" is alleged to instruct the claimed dosing regimens Compl. ¶131 Compl. ¶133

U.S. Patent No. 12,453,755 - "GIP/GLP1 Agonist Compositions"

• Technology Synopsis: This patent covers a method of treating diabetes by administering a pharmaceutical composition containing tirzepatide within specified concentration ranges for it and its excipients, including dibasic sodium phosphate, NaCl, and phenol Compl. ¶153
• Asserted Claims: At least independent claim 1 Compl. ¶154
• Accused Features: The proposed labeling for Defendants' "Proposed ANDA No. 221733 Product" is alleged to instruct and encourage the administration of the claimed composition for treating diabetes Compl. ¶154

U.S. Patent No. 12,453,756 - "GIP/GLP1 Agonist Compositions"

• Technology Synopsis: This patent claims a pharmaceutical composition containing tirzepatide and a specific concentration range of NaCl, where the composition has a pH of about 6.5 to 7.5 Compl. ¶172 This is directed at achieving a stable, injectable formulation.
• Asserted Claims: At least independent claim 1 Compl. ¶173
• Accused Features: Defendants' Proposed ANDA Products are alleged to be compositions that comprise the elements of the claim, including tirzepatide and NaCl within the claimed concentration and pH ranges Compl. ¶173

U.S. Patent No. 12,453,758 - "Methods of Using a GIP/GLP1 Co-agonist for Diabetes"

• Technology Synopsis: This patent covers a method of improving weight management by administering a GIP:GLP-1 Peptide with a specific receptor agonist potency ratio in a multi-dose titration schedule Compl. ¶189 The claim specifies a four-dose escalation regimen similar to that in the '987 Patent.
• Asserted Claims: At least independent claim 1 Compl. ¶190
• Accused Features: The proposed labeling for Defendants' "Proposed ANDA No. 221732 Product" is alleged to instruct and encourage the claimed multi-step dosing method for improving weight management Compl. ¶190

U.S. Patent No. 12,616,740 - "Methods of Using a GIP/GLP1 Co-agonist for Therapy"

• Technology Synopsis: This patent covers methods of treating type 2 diabetes and obesity by administering tirzepatide in a specific once-weekly, multi-step dose escalation regimen Compl. ¶208 Compl. ¶210 The regimen involves a 2.5 mg starting dose for four weeks, followed by 2.5 mg incremental increases to a maintenance dose.
• Asserted Claims: At least independent claims 1 and 6 Compl. ¶212
• Accused Features: The proposed labeling for Defendants' "Proposed ANDA No. 221733 Product" and "Proposed ANDA No. 221732 Product" is alleged to instruct the claimed dosing regimen Compl. ¶209 Compl. ¶211

U.S. Patent No. 12,629,404 - "GIP/GLP1 Agonist Compositions"

• Technology Synopsis: This patent is directed to a pharmaceutical composition containing tirzepatide and NaCl within a specific concentration range, having a pH of about 6.5 to 7.5, and being "free of preservative" Compl. ¶231
• Asserted Claims: At least independent claim 1 Compl. ¶232
• Accused Features: Defendants' Proposed ANDA Products are alleged to be compositions that comprise the elements of the claim, including being free of preservative Compl. ¶232

III. The Accused Instrumentality

Product Identification

The accused instrumentalities are Defendants' "Proposed ANDA Products" as described in ANDA Nos. 221733 and 221732, which are proposed generic versions of Lilly's Mounjaro® and Zepbound® (tirzepatide) autoinjectors Compl. ¶1

Functionality and Market Context

• The complaint alleges these are proposed generic drugs containing tirzepatide as the active pharmaceutical ingredient Compl. ¶52 The products are intended to be marketed as bioequivalent to Mounjaro® and Zepbound® for uses including improving glycemic control in patients with type 2 diabetes and for chronic weight management Compl. ¶1 Compl. ¶53
• The Proposed ANDA Products are presented in multiple strengths, including 2.5, 5, 7.5, 10, 12.5, and 15 mg/0.5 mL Compl. ¶1 The complaint alleges that upon approval, these products will be marketed as direct competitors to Lilly's branded products Compl. ¶1

IV. Analysis of Infringement Allegations

'780 Patent Infringement Allegations

Claim Element (from Independent Claim 1)	Alleged Infringing Functionality	Complaint Citation	Patent Citation
A compound of Formula: YX1EGTFTSDYSIX2LDKIAQKAX3VQWLIAGGPSSGAPPPS;	Defendants' Proposed ANDA Products contain tirzepatide, which is a compound with the structural formula corresponding to the claim. The complaint provides a visual diagram of the tirzepatide structure.	¶59	col. 29:4-10
wherein X1 is Aib; X2 is Aib;	The accused tirzepatide molecule has Aib at positions 2 and 13.	¶59	col. 29:10-11
K at position 20 is chemically modified through conjugation to the epsilon-amino group of the K side-chain with ([2-(2-Amino-ethoxy)-ethoxy]-acetyl)2-(yGlu)a-CO-(CH2)b-CO2H wherein a is 1 to 2 and b is 10 to 20;	The accused tirzepatide molecule has the specified chemical modification at the lysine (K) at position 20.	¶59	col. 29:11-15
X3 is Phe or 1-Nal;	The accused tirzepatide molecule meets this limitation.	¶59	col. 29:15-16
and the C-terminal amino acid is optionally amidated as a C-terminal primary amide (SEQ ID NO: 11),	The accused tirzepatide molecule is amidated as a C-terminal primary amide.	¶59	col. 29:16-17
or a pharmaceutically acceptable salt thereof.	The accused product contains tirzepatide or a pharmaceutically acceptable salt thereof.	¶59	col. 29:17-18

'820 Patent Infringement Allegations

Claim Element (from Independent Claim 1)	Alleged Infringing Functionality	Complaint Citation	Patent Citation
A pharmaceutical composition comprising tirzepatide, or a pharmaceutically acceptable salt thereof;	Defendants' Proposed ANDA Products are pharmaceutical compositions that contain tirzepatide or a salt thereof.	¶76	col. 10:42-43
NaCl at a concentration from 6.2 mg/mL to 9.5 mg/mL;	The Proposed ANDA Products allegedly contain NaCl at a concentration within the claimed range.	¶76	col. 10:44-45
and dibasic sodium phosphate.	The Proposed ANDA Products allegedly contain dibasic sodium phosphate.	¶76	col. 10:46

Identified Points of Contention

• Scope Questions: For the numerous patents claiming methods of use with specific dosing regimens (e.g., '987, '382, '740, '758 Patents), a central question will be whether the Defendants' proposed product labeling instructs, encourages, or suggests those exact regimens to physicians and patients, thereby inducing infringement. Minor differences in the described dosing instructions between the label and the claims could be a significant point of dispute. For the composition patents, a question is whether the term "about" preceding many concentration ranges (e.g., '623 Patent, claim 1) provides a scope that covers formulations that may not be strictly within the numerical limits.
• Technical Questions: A primary technical question is one of direct comparison: does the formulation specified in the Defendants' ANDAs fall within the literal scope of the claimed concentration ranges in patents like the '820 and '756 Patents? The complaint makes a conclusory allegation of infringement Compl. ¶76 but does not provide the specific formulation from the ANDAs, suggesting this will be a core subject of discovery and expert analysis. The complaint includes a chemical structure for tirzepatide, indicating Lilly's belief that the active ingredient itself reads on the compound claims of the 9474780 patent Compl. ¶59

V. Key Claim Terms for Construction

'780 Patent

The complaint does not provide sufficient detail for analysis of key claim terms for the '780 Patent beyond the direct structural comparison.

'820 Patent

• The Term: "dibasic sodium phosphate"
• Context and Importance: This term is a required excipient in the formulation claimed by the '820 Patent Compl. ¶75 The precise definition is critical because different hydrated forms of the substance exist, and the specific form used could be a basis for a non-infringement argument. Practitioners may focus on whether the term is limited to the anhydrous form or also encompasses various hydrated forms, which could affect concentration calculations and infringement analysis.
• Intrinsic Evidence for Interpretation:
  • Evidence for a Broader Interpretation: The independent claim itself simply recites "dibasic sodium phosphate" without specifying a hydration state, which may support an interpretation that any form of the chemical is covered '820 Patent, col. 10:46
  • Evidence for a Narrower Interpretation: The specification provides an example formulation in Table 3 that explicitly lists "Sodium phosphate dibasic 7H2O," the heptahydrate form '820 Patent, col. 4:55-64, Table 3 A defendant may argue this specific embodiment limits the claim term to a particular hydrated form.

VI. Other Allegations

• Indirect Infringement: The complaint alleges that Defendants will actively induce infringement of the method-of-use patents (e.g., '623, '987, '382, '755, '758, '740 patents) by providing proposed labeling that instructs and encourages physicians and patients to administer the Proposed ANDA Products according to the patented methods (Compl. ¶102; Compl. ¶121; Compl. ¶142). Contributory infringement is alleged on the basis that the Proposed ANDA Products are especially made or adapted for use in the patented methods and are not suitable for substantial noninfringing use (Compl. ¶105; Compl. ¶124; Compl. ¶147).
• Willful Infringement: The complaint alleges that Defendants had knowledge of the asserted patents before filing this lawsuit, based at a minimum on the patents' listing in the FDA's Orange Book and their inclusion in Defendants' own Notice Letters to Lilly (Compl. ¶67; Compl. ¶84; Compl. ¶101). These allegations of pre-suit knowledge may support a claim for willful infringement, for which the Plaintiff seeks enhanced damages and attorneys' fees (Compl. ¶¶54(e)-(f)).

VII. Analyst's Conclusion: Key Questions for the Case

• A core issue will be one of compositional identity: Does the formulation described in Defendants' ANDAs, including the identity and concentration of all excipients, fall within the literal scope of Lilly's various composition claims, particularly concerning terms like "dibasic sodium phosphate" and concentration ranges modified by "about"?
• A second central question will be one of induced infringement: Will Defendants' proposed product labeling be found to instruct or encourage physicians and patients to perform the specific, multi-step dose-escalation and maintenance regimens for treating diabetes and obesity as claimed in Lilly's method-of-use patents?
• Finally, an overarching issue, raised by the Defendants' Paragraph IV certification, will be patent validity: Although not detailed in the complaint, the Defendants will likely challenge the validity of Lilly's patents on grounds such as obviousness, particularly for the formulation and method-of-use claims, given the known properties of the tirzepatide compound.